Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...

The Nobel Prize in medicine was awarded to Victor Ambros, PhD, of the University of Massachusetts, and Gary Ruvkun, PhD, of ...

Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...

Drugs Market Growth is Driven by Rising Consumer Awareness, Growth of Lifestyle Diseases, and Expanding Distribution Channels Drive Market Growth; U.S. and Asia-Pacific Regions See Notable ...

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals. It has its own manufacturing facility at Goa. It sells products through independent ...

NICE has backed the drug after rejecting it earlier this year due to an “improved commercial arrangement” with Sanofi – in other words a price discount. Cablivi was also recommended for NHS ...

The Indian pharmaceutical sector faces mixed growth with a 12% YoY and 5% QoQ rise while IPM growth is projected at 8%.